1.Identification of Hydrocotyle sibthorpioides and its adulterants by HPLC fingerprint
Shina XU ; Xiangpei WANG ; Yichun SUN ; Fengyun JIN ; Yanni MA
Chinese Traditional Patent Medicine 2010;(2):173-176
AIM: To establish HPLC fingerprint for the identification of Hydrocotyle sibthorpioides and its adulterants. METHODS: The chromatographic seperation was performed on a Diamonsil C_(18) (250 mm×4.6 mm,5 μm)with a mobile phase consisting of acetonitrile-0.1% phosphoric acid, gradient eluent, at the flow rate of 1.0 mL/min. The UV detection was set at 340 nm. RESULTS: There was an apparent difference in fingerprint between Hydrocotyle sibthorpioides and its adulterants. CONCLUSION: The method is stable and reliable with a good reproducibility andprovides a reference standard for identifying Hydrocotyle sibthorpioides and its adulterants.
2.Identification of Hydrocotyle sibthorpioides and its adulterants by HPLC fingerprint
Shina XU ; Xiangpei WANG ; Yichun SUN ; Fengyun JIN ; Yanni MA
Chinese Traditional Patent Medicine 1992;0(02):-
AIM: To establish HPLC fingerprint for the identification of Hydrocotyle sibthorpioides and its adulterants. METHODS: The chromatographic seperation was performed on a Diamonsil C_18(250 mm?4.6 mm,5 ?m)with a mobile phase consisting of acetonitrile-0.1% phosphoric acid,gradient eluent,at the flow rate of 1.0 mL/min.The UV detection was set at 340 nm. RESULTS: There was an apparent difference in fingerprint between Hydrocotyle sibthorpioides and its adulterants. CONCLUSION: The method is stable and reliable with a good reproducibility and provides a reference standard for identifying Hydrocotyle sibthorpioides and its adulterants.
3.Identification of clematis raw drugs by HPLC fingerprint
Xiangpei WANG ; Jie HUANG ; Fengyun JIN ; Yichun SUN ; Hongmei WU ; Shina XU
Chinese Traditional Patent Medicine 1992;0(05):-
AIM:To establish HPLC fingerprint for the root and rhizome of Clematis uncinata Champ and to compare the differences of clematis and Clematis uncinata in fingerprint. METHODS:Based on 10 batches of Clematis unciuata Champ,its chromatographic seperation was performed on Diamonsil C18 (250 mm ? 4. 6 mm,5 ?m)with a mobile phase consisting of acetonitrile -0.05% phosphoric acid,gradient eluent,at the flow rate of 0. 8 mL/min. The UV detection was set at 210 nm. RESULTS:The mutual mode to HPLC-UV fingerprints was set up,and the 23 mutual peaks were indicated. The similarities were compared among Cleuatis uncinata Champ and substitutes collected from different sources there were apparent difference in fingerprint. CONCLUSION:The method is stable and reliable with a good reproducibility and provides a reference standard for identifying medicinal clematis.
4.Coffee colored pleural fluid-abdominal cyst-erythema nodosum
Li WANG ; Long QIAN ; Shuguang SHAN ; Jiafeng SUN ; Hangcheng ZHOU ; Ying WANG ; Xiangpei LI
Chinese Journal of Rheumatology 2011;15(7):460-464,后插1
Objective To discuss the diagnosis and treatment of systemic lupus erythematosus(SLE)patients associated with pancreatic pleural effusion and pancreatic:panniculitis.Methods Retrospectively analyzed the clinical data,therapy and experiences.Results A 40-year-old female SLE patient associated with pancreatitis,huge pancreatic pseudocysts,pancreatic pleural effusion,pancreatic panniculitis.Abdominal computed tomography(CT)showed an edematous swelling of the pancreas and several pseudocysts,the biggest one measuring 230 mm×95 am.Markedly elevated amylase (11 327 U/L)was contained in the massive pleural effusion.Erythema nodosum tissue pathology revealed the pancreatic panniculitis.The pscudocyst did not completely resolve with high-dose steroid.Growth hormone release inhibiting hormone (GIH),ulinastatin,nasojejunal feeding,and it was later complicated by infection and rupture.After a surgical percutaneous drainage for the complicated pseudocyst,the clinical symptoms and signs were markedly improved.Conclusion This case shows the importance of performing eady drainage rather than conservative treatment for pancreatic pseudocyst in patients with lupus-associated pancreatitis.
5.Expression and clinical significan ce of miR-326 on regulatory T cells of patients with systemic lupus erythematosus
Xiaoge SUN ; Jinhui TAO ; Nan XIANG ; Xiaomei LI ; Guosheng WANG ; Xuan FANG ; Chao DAI ; Min ZHANG ; Li JIN ; Xiangpei LI
Chinese Journal of Rheumatology 2016;(1):8-12
Objective To analyze the association of miR-326 mRNA expression level on regulatory T cells between clinical manifestations of patients with systemic lupus erythematosus (SLE), in order to inves-tigate the role of miR-326 on Treg cells and pathogenesis as well as its association with disease activity of SLE. Methods Twenty milimeter anti-coagulated peripheral blood was obtained from 52 SLE patients and 20 healthy controls. Treg were purified by MACS from peripheral blood, in which the quantity of miR-326 and Ets-1 mRNA were assessed by real-time polymerase chain reaction (PCR). Data were analyzed by using Mann-Whitney U test and Spearman correlation analysis. Results Compared with healthy controls [0.921(0.345, 1.879)], the expression of miR-326 mRNA level was significantly higher in Treg from SLE patients [2.927 (0.518, 8.662) (Z=-3.756, P<0.05). The difference between new-onset SLE patients [8.878(5.922, 12.466)] and recurrence group [3.512(0.582, 11.223)] with healthy controls was significant (Z=-2.135, Z=-4.928, P<0.05). The expression level of miR-326 in new-onset SLE patients was higher than inactive SLE patients (Z=-4.928, P<0.05). Significant difference of the expression level of miR-326 mRNA was found between new-onset SLE patients with serous cavity effusion [7.606(0.656, 16.795)] and new-onset SLE patients without it [1.840(0.576, 13.025)](Z=4.263, P<0.05). Our analysis showed that significant positive correlation was found between the expression of miR-326 mRNA in Treg with CRP (rs=0.481, P<0.05) and anti-C1q antibody (rs=0.729, P<0.05) from new-onset SLE patients. Conclusion The expression level of miR-326 is upregulated in Treg from SLE patients and is associated with disease active index, which suggests that miR-326 in Treg may participate the pathological process and disease activity in SLE.
6.Nationwide multicentre clinical research on flurbiprofen cataplasm for treating patients with osteoarthritis pain
Hua YE ; Xiaoxia ZUO ; Jieruo GU ; Ping ZHU ; Hejian ZOU ; Xiangpei LI ; Shaoxian HU ; Zhiyi ZHANG ; Lingyun SUN ; Zhanguo LI
Chinese Journal of Rheumatology 2012;16(9):606-610
ObjectiveTo study the effect and safety of flurbiprofen cataplasm on osteoarthritis pain in Chinese patients.MethodsOne hundred and eighty-three patients were divided into flurbiprofen cataplasm group,indometacin cataplasm group and Qizheng-xiaotong plaster group randomly.The score of pain,stiffness and physical function were analyzed with WOMAC scale and adverse reactions were also assessed.KruskalWallis H test,Nemenyi test and CMH tese were used.ResultsAfter treatment,the VAS value of the three groups decreased significantly and the VAS difference value of the flurbiprofen cataplasm group changed the most significantly(the changes of VAS value in flat walking,up and down stairs,nighttime,rest and weightbearing were 31±21,35±20,24±19,20±18 and 37±20 respectively).Meanwhile,the value of stiffness and physical function decreased significantly.In terms of safety,flurbiprofen cataplasm group and the indome-tacin cataplasm group were better than Qizheng-xiaotong plaster group.But in sense of constriction,the flurbiprofen cataplasm group was better than the indometacin eataplasm group.ConclusionFlurbiprofen Cataplasm,with its favorable analgesic effect,is suitable for general clinical use.It can reduce stiffness,improvephysical function,and has good safety profile.
7.Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
Chunde BAO ; Shunle CHEN ; Yueying GU ; Zhiying LAO ; Liqing NI ; Qiang YU ; Jianhua XU ; Xiangpei LI ; Jialing LIU ; Lingyun SUN ; Peigen HE ; Jiliang MA ; Shuyun XU ; Changhai DING
Chinese Medical Journal 2003;116(8):1228-1234
OBJECTIVETo evaluate the efficacy and safety of leflunomide in comparison with methotrexate (MTX) on patients with rheumatoid arthritis (RA) in China.
METHODSFive hundred and sixty-six patients with active rheumatoid arthritis were randomly assigned to receive leflunomide at 20 mg once daily or MTX at 15 mg once weekly in a controlled trial. Five hundred and four patients completed the 12-week treatment and some patients continued the treatment for 24 weeks.
RESULTSBoth leflunomide and MTX could improve the symptoms, signs, and joint function, but there were no changes in X-ray observations of patients with rheumatoid arthritis. In the leflunomide group, the overall rates of effectiveness at 12 weeks and 24 weeks were 86.94% and 92.31% respectively; the rates of remarkable improvement were 64.95% and 79.81% respectively. In the MTX group, the overall rates of effectiveness at 12 weeks and 24 weeks were 84.04% and 83.15% respectively; the rates of remarkable improvement were 56.81% and 75.28% respectively. According to intent-to-treat analysis, the ACR 20% response rates at 12 weeks and 24 weeks in the leflunomide group were 62.54% and 67.18% respectively, compared with 60.08% and 61.32% respectively in MTX group. No statistical differences were shown in the efficacy between the two groups (P > 0.05). The adverse events in the leflunomide group were gastrointestinal symptoms, skin rash, alopecia, nervous system symptoms, decreased leukocyte count, and elevation of alanine aminotransferase (ALT). Most of these side effects were mild and transient. The incidence of adverse events in the leflunomide group was 16.84%, significantly lower than that in MTX group (28.17%, P = 0.002).
CONCLUSIONSLeflunomide is effective in the treatment of RA with less adverse events than MTX. Its efficacy is similar to MTX, but the incidence of adverse events and the rate of withdrawal due to adverse events were lower in the leflunomide group than in MTX group.
Antirheumatic Agents ; adverse effects ; therapeutic use ; Arthritis, Rheumatoid ; drug therapy ; Female ; Growth Inhibitors ; adverse effects ; therapeutic use ; Humans ; Immunosuppressive Agents ; adverse effects ; therapeutic use ; Isoxazoles ; adverse effects ; therapeutic use ; Male ; Methotrexate ; adverse effects ; therapeutic use ; Middle Aged
8.Introduction to revision of Technical Specification for Occupational Health Surveillance
Chen YU ; Dehong LI ; Daoyuan SUN ; Zubing WANG ; Chaoqiang JIANG ; Xunmiao ZHANG ; Yongjian YAN ; Weiming YUAN ; Yiqun XUAN ; Xin QIAO ; Yujing XIA ; Qiuhong ZHU ; Qiang HOU ; Hong WANG ; Yiwen JIANG ; Xuetao ZHANG ; Fang QI ; Xiangpei LÜ ; Huanqiang WANG
China Occupational Medicine 2023;50(2):209-216
To revise GBZ 188 Technical Specification for Occupational Health Surveillance based on national laws, regulations, standards, specifications and legal documents of occupational disease, and combination with the actual situation in China. The main modifications are as follows: the occupational health surveillance for workers exposed to toluene (xylene may implement by reference), bromopropane, methyl iodide, ethylene oxide, chloroacetic acid, indium and its compounds, coal tar, coal tarasphalt, asphalt, β-naphthylamine, dust of metal and its compounds(tin, iron, antimony, barium and its compounds), hard metal dust, erionite dust, low temperature, laser, tick-borne encephalitis virus, Borrelia burgdorferi, and human immunodeficiency virus, for scraper or grind operators, and underground workers using squatting or kneeling position, crawling position, side-lying position, or shoulder position for a long period of time are included. The emergency health screening for workers exposed to arsenic, fluorine and its inorganic compounds, and acrylamide are included. The occupational medical examination (OME) for workers exposed to amino and nitro compounds of benzene, phosgene, monomethylamine, organic fluorine and dimethyl sulfate has been adjusted and made mandatory, with corresponding assessments required upon leaving the job. The special occupational health surveillance for workers exposed to mycobacterium tuberculosis and hepatitis virus is removed. The OME conclusion of reexamination is removed, and standardize recheck/additional inspection requirements. The optional items in OME performed before, during and after leaving post are removed, but the optional items in emergency medical examination are retained. Additional OME items are added. The Guideline for OME Summary Reports is added as informative appendix, and so on. The revised GBZ 188 Technical Specification for Occupational Health Surveillance is more scientific and practical.
9.Study on anti-inflammatory effects and mechanism of Zhuang medicine Tongfeng li’an capsules on gouty arthritis
Xiangpei ZHAO ; Nana DU ; Fengzhen LI ; Jianlong SHU ; Chaoyang LONG ; Xiaosu ZOU ; Zongxi SUN
China Pharmacy 2023;34(7):814-818
OBJECTIVE To investigate the anti-inflammatory effects and mechanism of Zhuang medicine Tongfeng li’an capsules on gouty arthritis in combination with in vivo and in vitro experiments. METHODS Sixty rats were randomly divided into normal group, model group, positive control group (27 mg/kg allopurinol+0.27 mg/kg colchicine), Tongfeng li’an capsules low- dose, medium-dose and high-dose groups (2.2, 4.5, 9.0 g/kg), with 10 rats in each group. Except for normal group, gouty arthritis model of rats was induced in other groups. Rats in each administration group were given corresponding drugs intragastrically, and rats in the normal group and model group were given equal volume of water intragastrically for 14 consecutive days. The degree of ankle joint swelling, serum level of interleukin-1β (IL-1β) and protein expressions of nuclear factor kappa-B (NF-κB) in synovial tissue were detected, and the histopathological changes of synovium tissue in the ankle joint of rats were observed. The inflammation model was established by stimulating RAW264.7 cells with lipopolysaccharide. After Tongfeng li’an capsules (62.5, 125, 250 μg/mL) were given, the levels of nitric oxide (NO), reactive oxygen species (ROS) and IL-1β in the cells and protein expression of NF-κB were detected, and NF-κB localization in the cells was also determined. RESULTS Results of in vivo experiment showed that compared with normal group, the swelling degree of the ankle joint, serum IL-1β level and protein expression of NF-κB in synovium tissue were all increased significantly in model group (P<0.05); pathological changes such as synovial hyperplasia, edema, vascular congestion, capillary hyperplasia, and increased inflammatory cells were observed. Compared with model group, the levels of above indexes were all decreased significantly in Tongfeng li’an capsules high-dose group (P<0.05), and most of the above indexes were significantly reduced in Tongfeng li’an capsules medium-dose and low-dose groups (P<0.05); synovial hyperplasia of the ankle joint improved, and the infiltration of inflammatory cells 2019BS044) decreased. Results of in vitro experiment showed that Tongfeng li’an capsule could significantly reduce the levels of NO, ROS and IL-1β and protein expression of NF-κB(P<0.01), and inhibit NF- κB nucleation. CONCLUSIONS Tongfeng li’ancapsules have good anti-inflammatory effect on gouty arthritis, and its mechanism may be related to the inhibition of NF-κB signaling pathway activity.
10.Progress on the relationship of aldehyde dehydrogenase 2 with human diseases and its small-molecule activators
Xiangpei SUN ; Xing GAO ; Fengping ZHAO ; Wentao WANG ; Tianyi ZHANG ; Wei TIAN ; Canhui ZHENG ; Xin CHEN
Journal of Pharmaceutical Practice and Service 2024;42(1):6-11
Aldehyde dehydrogenase 2 (ALDH2) is one of important factors against from the damage under oxidative stress in human body. A high proportion of East Asians carry ALDH2 inactive mutation gene. There are many diseases closely related to ALDH2, such as cardiovascular diseases, neurodegenerative diseases and liver diseases. Recent studies also have found that ALDH2 is associated with ferroptosis. Therefore, ALDH2 has becoming a potential target for the treatment of the above related diseases. Several types of small molecule activators with potential value of clinical application have been reported. The research progress on the structure and function of ALDH2 , the relationship with human diseases and its activators were summarized in this paper.